Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06123169
Other study ID # 2020/0423/HP
Secondary ID 2021-006991-18
Status Not yet recruiting
Phase Phase 3
First received
Last updated
Start date March 2024
Est. completion date June 2026

Study information

Verified date November 2023
Source University Hospital, Rouen
Contact Lilian Schwarz
Phone 0232888416
Email lilian.schwarz@chu-rouen.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main objective of the study is to compare 2 broad-spectrum antibiotic (Piperacillin / Tazobactam) treatment modalities, following pancreaticoduodenectomy in patients with preoperative biliary stent, to demonstrate the superiority of a 5-day post-operative antibiotic therapy to antibiotic prophylaxis on the occurrence of surgical site infections (SSI)


Description:

Despite cumulative efforts in surgery and perioperative management, the morbi-mortality rates of pancreatoduodenectomy (PD) remain high. The most frequent complications were sepsis and infectious complications 44%, hemorrhagic complications 36.6%, pulmonary complications 35.2%, shock 29.8% and pancreatic fistula 27.9%. PD is a technically complex procedure with substantial associated morbidity and mortality. Infectious complications have been reported to occur in as many as 30% of patients following open PD. Biliary colonization that arises from preoperative procedures for biliary drainage closely predicts infectious complications following PD. Besides biliary intervention, nutritional reserve and biliary or pancreatic anastomotic leaks are common factors linked to developing infectious complications following PD. D'Angelica et al. Recently demonstrated the superiority of Piperacillin-tazobactam compared with cefoxitin as antimicrobial prophylaxis for PD: a randomized clinical trial in JAMA, with a significant reduction of postoperative SSI rate. One of the main risk factors for infectious complications and especially surgical site infections, but also post-operative pancreatic fistula is bacteriobilia, defined by the bile contamination by microorganism(s) related to preoperative biliary drainage. A significant decrease in all-type SSI and organ-space SSI with Broad spectrum antibiotics was observed after open PD, as reported by Kone et al. or De Grandi et al. According to Kone et al. on subgroup analysis, only patients with preoperative biliary stents and/ or jaundice (61% of PD patients) had an association between Broad-abx and decreased SSI. Numbered of surgeons modified their antibiotic usage in this setting of preoperative biliary drainage, as we also observed in France, where more than 50% prescribed a broad spectrum antibiotherapy intraoperatively only (antibioprophylaxis) or for 3 to 5 days. The aim of this study is to determine whether a prophylactic treatment used only during surgery, or for 5 days with this treatment, in the clinical context of PD after biliary drainage, is effective in reducing surgical complications, particularly infectious ones. Such results could reduce the need for prolonged anti-infectious treatments and reoperations (surgical and radiological). Hospital stays could also be shortened, with a positive impact on your quality of life.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 326
Est. completion date June 2026
Est. primary completion date June 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Planned pancreaticoduodenectomy for periampullary neoplasms - Endoscopic or radiological pre-operative biliary drainage - Age = 18 years old - Patient able to comply with the study protocol, in the investigator's judgment - Patient affiliated with, or beneficiary of a social security (national health insurance) category - Person of full age having read and understood the information letter and signed the consent form - Women of childbearing potential (a woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile) with hightly effective contraception (Cf. CTFG) combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation, progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device (IUD), intrauterine hormone-releasing system ( IUS), bilateral tubal occlusion, vasectomised partner, sexual abstinence) since 1 month and during the duration of the study and a negative blood pregnancy test by beta-HCG at inclusion. - Women permanently sterile (hysterectomy, bilateral salpingectomy and bilateral oophorectomy. - Postmenopausal women: A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. However in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient. Exclusion Criteria: - Contraindication to PIPERACILLIN/TAZOBACTAM PANPHARMA 4g / 500mg powder for solution for injection in accordance with its SmPC - Patients allergic to beta-lactam antibiotics - Others pancreatic resection - Absence of preoperative biliary drainage - Surgical or anaesthesiological contra-indications: - non-controlled congestive heart failure - non-treated angina - recent myocardial infarction (in the previous year) - non-controlled AHT (SBP >160 mm or DBP > 100 mm, despite optimal drug treatment), long QT - major non-controlled infection - severe liver failure - Medical, geographical, sociological, psychological or legal conditions that would not permit the patient to complete the study or sign informed consent - Any significant disease, which, in the investigator's opinion, would exclude the patient from the study - Pregnant or parturient or breastfeeding woman or absence of contraceptionn - Person deprived of liberty by administrative or judicial decision or person placed under judicial protection, under guardianship or supervision - Simultaneous participation in another interventional research with the same primary endpoint.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Antibioprophylaxis (Piperacillin-tazobactam)
antibiotic prophylaxis during surgery
5 days Antibiotherapy (Piperacillin-tazobactam)
5 days Antibiotherapy from surgery

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Rouen

Outcome

Type Measure Description Time frame Safety issue
Primary presence of an organ/space SSI The primary End Point is the presence of an organ/space SSI determined according to the Centers for Disease Control and Prevention's national nosocomial infections surveillance system. Organ/space SSIs include postoperative pancreatic fistula (POPF) and bile leakage, with positive culture results. 90 days after the surgery
Secondary Infectious complications at post-operative Overall postsurgical morbidity, graded according to the Dindo/Clavien classification and CCI score day 90
Secondary Correlation between post-operative bacteriological samples and intraoperative bile samples Correlation between post-operative bacteriological samples and intraoperative bile samples (presence of bacterial strains) day 90
Secondary Bacteriological resistance profiles Incidence of fungal contamination day 90
Secondary Correlation between bacteriological and fungal contaminations Correlation between bacteriological and fungal contaminations (presence of bacterial strains and fungal contamination) day 90
Secondary Specific morbidity due to pancreatic fistula, graded according to the International Study Group of Pancreatic Fistula (ISGPF) criteria Specific morbidity due to pancreatic fistula, graded according to the International Study Group of Pancreatic Fistula (ISGPF) criteria day 90
Secondary Readmission rates and Duration of hospitalization Readmission rates and Duration of hospitalization day 90
See also
  Status Clinical Trial Phase
Completed NCT00827931 - Study Of Tranexamic Acid For The Reduction Of Blood Loss In Patients Undergoing Major Abdominal Surgery Phase 4
Completed NCT05567094 - The Effect of Perioperative DEXamethasone on Postoperative Complications After PANcreaticoduodenectomy Phase 4
Recruiting NCT05523713 - Development and Validation of a Predictive Score for Surgical Site Infections Phase 3
Completed NCT01988519 - Randomized Controlled Trial Comparing Closed-suction Drain Versus Passive Gravity Drain Following Pancreatic Resection N/A
Completed NCT01758172 - Comparison of Hemodynamic Effects of Two Colloid Therapies in Post-operative Patients Undergoing Pancreaticoduodenectomy Phase 3
Recruiting NCT04118881 - Ear Acupuncture Preventing Delayed Gastric Emptying. N/A
Recruiting NCT04798560 - Identifing Risk Factors for Pancreaticojejunostomy Leakage Following Pancreaticoduodenectomy
Recruiting NCT04559269 - Microsleep 1, Micro-sleep During Maintenance Wakefulness Tests
Recruiting NCT06119880 - The Effect of PERT on Patients Undergoing Pancreaticoduodenectomy Phase 4
Not yet recruiting NCT05389917 - Three-Dimensional Vascular Reconstruction of the Pancreas on Multidetector Computed Tomography Images and Its Impact on Patients Undergoing Pancreaticoduodenectomy
Completed NCT02807701 - Minimally Invasive Pancreatico-duodenectomy N/A
Recruiting NCT01428050 - The Use of a Restrictive Fluid Regimen With Hypertonic Saline for Patients Undergoing Pancreaticoduodenectomy Phase 2
Completed NCT00668876 - Effects of Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Phase 4
Recruiting NCT06322680 - Impact of External Drainage of the Main Pancreatic Duct and Common Bile Duct on Pancreatic Fistula Following Pancreaticoduodenectomy N/A
Not yet recruiting NCT05314244 - Comparison Between Pylorus-resecting and Preserving Pancreaticoduodenectomy on Delayed Gastric Emptying and Nutrition N/A
Completed NCT00931554 - Randomized Trial of Early Versus Standard Drainage Removal After Pancreatic Resections N/A
Completed NCT00200148 - Acute Normovolemic Hemodilution Versus Standard Intraoperative Management in Patients Having Hepatic Resection and Pancreaticoduodenectomy Phase 3
Recruiting NCT04342923 - Early POstoperative BIomarkers in PancreatoDuodenectomy: a Spanish Nationwide Study
Recruiting NCT03785743 - Comparing Laparoscopic and Open Surgery for Pancreatic Carcinoma N/A
Completed NCT03791450 - Investigation of Pancreaticoduodenectomy